{
  "docId": "019de076-0bfb-77a4-9766-824e83d61c36",
  "docSlug": "78f42e9d8d70fea2dc2370a17955f7e7",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 37,
  "pageCount": 52,
  "prevPage": 36,
  "nextPage": 38,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 32,
  "notes": "Data cut-off: 8 Aug 2023. Includes specific footnotes regarding dose modifications and discontinuations.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/37",
  "deckHref": "/decks/019de076-0bfb-77a4-9766-824e83d61c36",
  "deckJsonHref": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json",
  "deckAnchorHref": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-37",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.07,
        "y": 0.83
      },
      "kind": "disclaimer",
      "text": "Data cut-off: 8 Aug 2023. ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; CPK, creatinine phosphokinase; DLT, dose-limiting toxicity; TRAE, treatment-related adverse event. a TRAEs resulting in treatment discontinuation were Grade 4 ALT/Grade 3 AST elevations (50 mg QD) and intolerable Grade 2 constipation (occurred at 100 mg QD following dose increase from 50 mg QD). b TRAEs resulting in dose-reduction were Grade 2 ALT/AST elevation (50 mg), Grade 3 ALT/AST elevation (100 mg), Grade 2 nausea/cognitive disturbance (150 mg), Grade 4 CPK elevation (200 mg), and Grade 3 neutropenia (200 mg). Treatment continues at the reduced dose for 4 of these 5 patients. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "58338d70-d8f1-486b-ac8f-0eeb72ea5a61",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.35,
        "x": 0.07,
        "y": 0.28
      },
      "kind": "list",
      "text": "MTD has not been identified; 1 DLT: transient asymptomatic Grade 4 CPK increase. Infrequent TRAEs requiring dose modification: 2% discontinued, 5% dose-reduced. Profile consistent with avoiding TRK-related neurotoxicities.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1244f7b5-22e7-4a20-ac94-1fda80b08b2e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.5,
        "x": 0.42,
        "y": 0.25
      },
      "kind": "table",
      "text": "Treatment-Related Adverse Events (TRAEs) in ≥ 5% of patients. All Treated Patients (N = 93). Table columns: Grade 1, Grade 2, Grade ≥3, Any Grade.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa5bbd0b-2112-4f74-9266-196df3b24f57",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "Preliminary Safety Profile | Favorable and Consistent with ALK-Selective, TRK-Sparing Design of NVL-655",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b8166b41-5249-4d80-9808-b8c598d34e12",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 45,
      "from": 13,
      "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}